Serotonin Pharmacology

Correct Answer

B — Buspirone

Rationale

Buspirone is classified as a partial agonist at the serotonin type 1A receptor and is used as an anxiolytic. Ondansetron is a serotonin type 3 antagonist used for nausea and vomiting. Sumatriptan is a serotonin type 1B/1D agonist used in acute migraine. Cyproheptadine is a serotonin type 2 antagonist used in serotonin syndrome.

Correct Answer

C — Ondansetron

Rationale

Ondansetron is classified as a serotonin type 3 receptor antagonist, used to prevent chemotherapy-induced nausea and vomiting. Buspirone is a serotonin type 1A partial agonist. Sumatriptan is a serotonin type 1B/1D agonist. Prucalopride is a selective serotonin type 4 agonist.

Correct Answer

A — Cyproheptadine

Rationale

Cyproheptadine is classified as a serotonin type 2 receptor antagonist and is the first-line pharmacological treatment for serotonin syndrome. Buspirone is a serotonin type 1A partial agonist. Ondansetron is a serotonin type 3 antagonist. Prucalopride is a selective serotonin type 4 agonist.

Correct Answer

D — Sumatriptan

Rationale

Sumatriptan is classified as a selective serotonin type 1B and type 1D receptor agonist and is the prototype triptan used in acute migraine. Cyproheptadine is a serotonin type 2 antagonist. Ondansetron is a serotonin type 3 antagonist. Buspirone is a serotonin type 1A partial agonist.

Correct Answer

A — Dopamine D2 receptor antagonist and serotonin type 4 partial agonist

Rationale

Metoclopramide is classified as both a dopamine D2 receptor antagonist and a serotonin type 4 partial agonist — a dual classification that accounts for its antiemetic and prokinetic actions. Selective serotonin type 3 antagonism describes ondansetron and the setron class. Serotonin type 1B/1D agonism describes the triptans. Serotonin type 2 antagonism describes cyproheptadine.

Correct Answer

C — Prucalopride

Rationale

Prucalopride is classified as a selective serotonin type 4 receptor agonist, approved for chronic idiopathic constipation. Cyproheptadine is a serotonin type 2 antagonist. Ondansetron is a serotonin type 3 antagonist. Buspirone is a serotonin type 1A partial agonist.

Correct Answer

A — Enterochromaffin cells of the gastrointestinal mucosa

Rationale

Enterochromaffin cells lining the gastrointestinal mucosa contain approximately 90 to 95 percent of total body serotonin. These specialized neuroendocrine cells synthesize and release serotonin in response to luminal stimuli, coordinating peristalsis. Raphe nuclei neurons are the primary source of central nervous system serotonin but contain a small fraction of total body serotonin. Platelets store serotonin by uptake from portal blood via the serotonin transporter, but do not synthesize it. Adrenal chromaffin cells synthesize catecholamines, not serotonin.

Correct Answer

C — Platelets actively take up serotonin from portal blood via the serotonin transporter

Rationale

Platelets do not synthesize serotonin — they lack tryptophan hydroxylase. Instead, the serotonin transporter expressed on platelet surface membranes actively concentrates serotonin from portal blood into dense granules. This active transport mechanism is why selective serotonin reuptake inhibitors, by blocking the serotonin transporter, deplete platelet serotonin stores and reduce platelet reactivity. Passive diffusion cannot achieve the high intragranular concentrations found in platelets. Raphe nuclei serotonin does not cross the blood-brain barrier and does not contribute to peripheral platelet loading.

Correct Answer

B — It is a ligand-gated ion channel rather than a G-protein coupled receptor

Rationale

The serotonin type 3 receptor is the only ionotropic serotonin receptor — a ligand-gated cation channel permeable to sodium, potassium, and calcium that produces rapid membrane depolarization upon serotonin binding. Every other serotonin receptor subtype (5-HT1 through 5-HT7) is a G-protein coupled receptor. Gi coupling describes the 5-HT1 family. Gq coupling with phospholipase C activation describes the 5-HT2 family. Gs coupling with cyclic AMP elevation describes the 5-HT4, 5-HT6, and 5-HT7 receptors.

Correct Answer

D — 5-Hydroxyindoleacetic acid — a urine biomarker elevated in serotonin-secreting tumors

Rationale

Monoamine oxidase A oxidizes serotonin to 5-hydroxyindoleacetic acid, which is excreted in urine. A 24-hour urinary 5-hydroxyindoleacetic acid level above 25 mg per day is the standard biochemical marker for diagnosing serotonin-secreting carcinoid tumors. 5-Hydroxytryptophan is a serotonin precursor, not a metabolite. Homovanillic acid is the urine metabolite of dopamine, not serotonin. Tryptamine is not a clinically used serotonin metabolite marker.

Correct Answer

A — Peripheral serotonin levels do not reflect central nervous system serotonergic activity

Rationale

Because serotonin cannot cross the blood-brain barrier, the central and peripheral serotonin pools are pharmacologically independent. Measuring plasma serotonin — which reflects primarily platelet content and gut turnover — provides no information about central serotonergic tone. This is clinically relevant: a patient's antidepressant response cannot be monitored by measuring blood serotonin levels. Selective serotonin reuptake inhibitors block the serotonin transporter in the brain, where serotonin is synthesized locally by raphe neurons. Enterochromaffin cells synthesize serotonin independently via peripheral tryptophan hydroxylase. Monoamine oxidase inhibitors act centrally because the drugs themselves cross the blood-brain barrier, even though serotonin does not.

Correct Answer

C — It antagonizes the serotonin type 2 receptor, blocking the receptor subtype responsible for clonus and hyperreflexia

Rationale

Excess stimulation of serotonin type 2A receptors produces the neuromuscular features of serotonin syndrome — clonus, hyperreflexia, and tremor. Cyproheptadine directly antagonizes serotonin type 2 receptors, reversing this component of the toxidrome. It does not block the serotonin transporter — that property belongs to selective serotonin reuptake inhibitors, which are causative agents in serotonin syndrome. Monoamine oxidase A is not inhibited by cyproheptadine. Dopamine D2 antagonism is the mechanism relevant to neuroleptic malignant syndrome, not serotonin syndrome.

Correct Answer

B — Clonus and hyperreflexia

Rationale

Clonus and hyperreflexia are the most specific neuromuscular features of serotonin syndrome, reflecting excess serotonin type 2A receptor stimulation at spinal cord interneurons. Lead-pipe rigidity is the hallmark of neuroleptic malignant syndrome, caused by central dopamine receptor blockade — not serotonin excess. Hyporeflexia and flaccid weakness suggest neuromuscular junction pathology or lower motor neuron disease, not either syndrome. Resting tremor with cogwheel rigidity is characteristic of parkinsonism from dopamine depletion. At the bedside, the presence of clonus points strongly toward serotonin toxicity.

Correct Answer

D — Cardiac valvulopathy from proliferation of valvular interstitial cells

Rationale

Serotonin type 2B receptors are expressed on cardiac valvular interstitial cells. Chronic agonism at this receptor subtype stimulates mitogenic pathways in these cells, producing fibrotic thickening of valve leaflets and ultimately causing regurgitation and stenosis — the mechanism underlying fenfluramine-associated valvular heart disease and ergotamine-related valvular damage. Bronchoconstriction is mediated by serotonin type 2A receptors in airway smooth muscle, not type 2B. Renal vasoconstriction is not a recognized 5-HT2B effect. QT prolongation results from cardiac ion channel blockade — a distinct mechanism seen with agents such as cisapride and ondansetron.

Correct Answer

B — Excess serotonergic activity from simultaneous inhibition of serotonin reuptake and serotonin degradation

Rationale

Fluoxetine blocks the serotonin transporter, preventing serotonin reuptake. Phenelzine is a non-selective irreversible monoamine oxidase inhibitor that blocks serotonin degradation. Together they cause serotonin to accumulate to toxic levels, producing the classic triad of serotonin syndrome: neuromuscular abnormalities (clonus, hyperreflexia), autonomic instability (hyperthermia, diaphoresis), and altered mental status. This is the most dangerous drug combination in psychopharmacology. Dopamine excess causes the lead-pipe rigidity of neuroleptic malignant syndrome, not clonus. Isolated norepinephrine excess produces a hypertensive crisis without clonus. Serotonin type 3 receptors mediate emesis, not the neuromuscular features of serotonin syndrome.

Correct Answer

A — It acts as a somatostatin analog, directly inhibiting serotonin secretion from tumor cells

Rationale

Octreotide is a long-acting somatostatin analog that binds somatostatin receptors on carcinoid tumor cells, directly suppressing their secretion of serotonin and other vasoactive mediators. This reduces circulating serotonin, controlling the flushing and diarrhea of carcinoid syndrome. It does not block serotonin type 2 receptors — that mechanism belongs to cyproheptadine. Telotristat ethyl, not octreotide, inhibits tryptophan hydroxylase to reduce serotonin synthesis. The serotonin transporter on platelets is blocked by selective serotonin reuptake inhibitors — octreotide has no effect on this transporter.

Correct Answer

C — It blocks serotonin type 2 receptors, opposing the receptor stimulation responsible for clonus and hyperreflexia

Rationale

Cyproheptadine is a serotonin type 2 receptor antagonist. In serotonin syndrome, excess serotonin type 2A receptor stimulation at cortical and spinal cord interneurons produces clonus, hyperreflexia, and tremor — the neuromuscular features that most specifically define the syndrome. By blocking this receptor, cyproheptadine directly counters these features. Inhibiting the serotonin transporter is the mechanism of the causative drugs, not the antidote. Monoamine oxidase A is not activated by any drug. Serotonin type 3 antagonism by ondansetron addresses nausea and vomiting, not the neuromuscular toxidrome.

Correct Answer

D — Serotonin type 3 receptor antagonists

Rationale

Chemotherapy damages the gastrointestinal mucosa, triggering enterochromaffin cells to release serotonin. This serotonin activates serotonin type 3 receptors on vagal afferent neurons in the gut wall and in the chemoreceptor trigger zone of the brainstem, generating the acute vomiting reflex. Serotonin type 3 antagonists — including ondansetron, granisetron, and palonosetron — block this receptor and are the mainstay of chemotherapy-induced nausea and vomiting prophylaxis. Serotonin type 1A partial agonists such as buspirone are used for anxiety. Serotonin type 2 antagonists such as cyproheptadine are used for serotonin syndrome. Serotonin type 4 agonists such as prucalopride promote gastrointestinal motility for constipation.